Papers by Eusebio Rubio-Aurioles
European Urology Supplements, 2006
The Journal of Sexual Medicine, May 7, 2022
Culture is a term used in several ways, we will adhere to the definition proposed by the Merriam-... more Culture is a term used in several ways, we will adhere to the definition proposed by the Merriam-Webster Dictionary in its first meaning: "The customary beliefs, social forms, and material traits of a racial, religious, or social group." 1
The Journal of Sexual Medicine, 2013
Introduction. Low sexual desire in men is a condition that has received little attention; neverth... more Introduction. Low sexual desire in men is a condition that has received little attention; nevertheless it occurs with high frequency. Clinicians are in need of clear guidelines to address this problem. Aim. To develop standardized operational procedures to be implemented with men presenting low sexual desire/ interest (LSD/I). Methods. Review of relevant evidence-based literature and published guidelines, integrated with expert opinion. Main Outcome. Operational procedures for LSD/I that are recommended for clinical practice with various degrees of support from published evidence. Results. A new classification scheme is proposed; LSD/I is proposed as an umbrella term for which hypoactive sexual desire disorder (HSDD) is only a subtype. The following standard operational procedures are described: (i) Detection of LSD/I: screening for LSD/I, screening for LSD/I in patients with other sexual dysfunctions; (ii) Diagnosis and assessment of etiology: diagnostic criteria for LSD/I, assessment of depression status, assessment of relationship status, assessment of endocrinologic status, diagnostic criteria for HSDD in men; (iii) Treatment: treatment of LSD/I secondary to low testosterone, treatment of LSD/I secondary to elevated prolactin, treatment of LSD/I secondary to other endocrinologic disorders, treatment of LSD/I secondary to depressive illness and or anxiety disorders, treatment of LSD/I secondary to relationship conflict and treatment of HSDD. A diagnostic and treatment algorithm is presented. Conclusions. LSD/I is a common condition that should be identified in patients; it is recommended that this condition be actively investigated by the clinician. Once the diagnosis of LSD/I in men is confirmed, a thorough search for possible causes needs to include both biological and psychological causes. Treatment should be etiologically oriented. Rubio-Aurioles E and Bivalacqua TJ. Standard operational procedures for low sexual desire in men. J Sex Med **;**:**-**.
Revista De Investigacion Clinica, 2004
The Journal of Sexual Medicine, May 1, 2012
To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment wit... more To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5 mg once a day (OaD) vs. tadalafil 20 mg or sildenafil 100 mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men Ն18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were analyzed with a mixed effects model for crossover design. Main Outcome Measures. The primary outcome measure was the Sexual Self-Confidence domain of the Psychological and Interpersonal Relationship Scales (PAIRS) between tadalafil OaD and sildenafil PRN. Secondary Outcomes Included. Time Concerns and Spontaneity domains of PAIRS, and the Self-Esteem and Relationship (SEAR) scale. Results. Men naive to tadalafil OaD were enrolled (N = 378), with 61-69% prior PDE5 inhibitor use. There were improvements in all PAIRS domains from baseline when comparing tadalafil OaD and PRN with sildenafil PRN (P < 0.001). The Sexual Self-Confidence domain improved from baseline and was 0.50 Ϯ 0.78 following tadalafil OaD, 0.5 Ϯ 0.72 for tadalafil PRN, and 0.39 Ϯ 0.67 for sildenafil PRN. The difference in least-squares mean was 0.12 Ϯ 0.04 (confidence interval [CI] = 0.04, 0.19; P = 0.001) between tadalafil OaD and sildenafil PRN and 0.01 Ϯ 0.04 (CI =-0.06, 0.08; P = 0.872) between tadalafil OaD and tadalafil PRN. The Time Concerns domain score was lower with tadalafil OaD than tadalafil PRN (P < 0.001). There were no differences in SEAR scores between treatments. Conclusions. Tadalafil OaD and tadalafil PRN compared with sildenafil PRN demonstrated greater improvements in Sexual Self-Confidence, Time Concerns, and Spontaneity. There was no significant difference in Sexual Self-Confidence between tadalafil OaD and tadalafil PRN. Changes in SEAR, the erectile function domain of the International Index of Erectile Function, and the Erectile Dysfunction Inventory of Treatment Satisfaction scores from baseline to end point were similar. Rubio-Aurioles E,
The Journal of Sexual Medicine, Oct 1, 2010
Introduction. Sexual problems in men and women are common; and physicians endorse many barriers t... more Introduction. Sexual problems in men and women are common; and physicians endorse many barriers to addressing these issues, including lack of knowledge about the diagnosis and management of sexual problems and inadequate training in sexual health communication and counseling. Aim. To update the recommendations published in 2004, from the International Consultation on Sexual Medicine (ICSM) relevant to the educational aspects of sexual health in undergraduate, graduate, and postgraducate medical education. Methods. A third international consultation in collaboration with the major sexual health organizations assembled over 186 multidisciplinary experts from 33 countries into 25 committees. Three experts from three countries contributed to this committee's review of Education in Sexual Medicine. Main Outcome Measure. Expert opinion was based on a comprehensive review of the medical literature, committee discussion, public presentation, and debate. Results. A comprehensive review about the current state of undergraduate, graduate, and postgraduate sexual health education worldwide is provided. Recommendations about ideal sexual health curricula across training levels are provided. Best methods for achieving optimal training approaches to sexual health communication and interviewing, clinical skills and management, and counseling are described. Conclusions. Current sexual health education for undergraduate and practicing physicians is inadequate to meet the advancing science and technology and increasing patient demand for high-quality sexual health care. There is a need for enhanced training in medical institutions responsible for physician sexual health training worldwide. Future training programs at all levels of medical education should incorporate standardized measures of sexual health clinical skills acquisition and assessments of the impact on patient outcomes into the design of educational initiatives.
The Journal of Sexual Medicine, Nov 1, 2006
Introduction. Data from head-to-head clinical trials of phosphodiesterase type 5 (PDE5) inhibitor... more Introduction. Data from head-to-head clinical trials of phosphodiesterase type 5 (PDE5) inhibitors are scarce, making it difficult for clinicians to differentiate among these agents to select the most appropriate treatment for their patients with erectile dysfunction (ED). Aim. This randomized, double-blind, crossover head-to-head clinical trial compared patient preference, efficacy, and safety of vardenafil and sildenafil in men with ED and diabetes, hypertension, and/or hyperlipidemia. Methods. Prospective analysis was performed on two studies in which 1,057 men were randomized to vardenafil 20 mg (N = 530) or sildenafil 100 mg (2 × 50 mg encapsulated tablets) (N = 527) for 4 weeks. Following a 1-week washout, patients switched treatment for 4 weeks. Main Outcome Measures. Patients were asked about overall preference: "Overall, which medication do you prefer?", plus 11 other preference questions relating to their ED treatment. Efficacy assessments after each treatment period included the erectile function (EF) domain score of the International Index of Erectile Function (IIEF); Sexual Encounter Profile (SEP) diary questions SEP2 and SEP3; Global Assessment Question (GAQ); and Treatment Satisfaction Scale (TSS). Data regarding adverse events were collected throughout the study. Results. A total of 931 men (mean age 57.9 years) were included in the intent-to-treat (ITT) population. Noninferiority of vardenafil over sildenafil was achieved for overall preference (vardenafil 38.9%; sildenafil 34.5%; and no preference 26.6%). Additionally, the change from baseline in the EF domain score of the IIEF achieved nominal significance for vardenafil over sildenafil (10.00 vs. 9.40; P = 0.0052). Patients also had a higher percentage of positive responses for vardenafil for SEP2, SEP3, GAQ, and 12 of 19 questions on the TSS. Both drugs were well tolerated. Conclusions. This randomized, double-blind, head-to-head trial in ED patients with cardiovascular risk factors demonstrated noninferiority of vardenafil for overall preference. Vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures. Both drugs were well tolerated. Rubio-Aurioles E, Porst H, Eardley I, and Goldstein I for the Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: A randomized, double-blind, pooled crossover study.
The Journal of Sexual Medicine, May 1, 2009
Clinical research on erectile dysfunction (ED) has focused primarily on the male and the impact o... more Clinical research on erectile dysfunction (ED) has focused primarily on the male and the impact of treatment on their erectile function (EF) and sexual quality of life. However, ED affects the quality of life of both the male and the female partner. The literature examining the impact on the female partner resulting from treating the male&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s ED is somewhat limited. To determine the efficacy of tadalafil 5 mg taken once daily compared with placebo on men&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s EF and sexual quality of life, and to determine the impact of this treatment on the female partner&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s sexual quality of life. The co-primary outcome measures for this study were changes from baseline to end point in the EF domain of the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) question 2 (SEP-2) and question 3 (SEP-3), and the Sexual Quality of Life (SQoL) domain of the Sexual Life Quality Questionnaire (SLQQ) (subject and…
The Journal of Sexual Medicine, Oct 1, 2009
Previous research has demonstrated that sildenafil citrate users alter dosing-sexual attempt beha... more Previous research has demonstrated that sildenafil citrate users alter dosing-sexual attempt behavior when switched to tadalafil. The impact of geography and culture on sexual behavior with phosphodiesterase type 5 (PDE5) inhibitor treatment has not been fully investigated. To describe and compare the changes in dosing-sexual attempt behavior with sildenafil citrate vs. tadalafil treatment across four distinct geographies: Asia, Australia/New Zealand (ANZ), Central Eastern Europe/Middle East (CEE/ME), and Latin America (LA). Data from a single-arm, open-label clinical trial conducted in 21 countries from November 2002 to May 2004 were used in this analysis. Men with erectile dysfunction and a history of &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt; or =6-week prior sildenafil citrate use continued sildenafil citrate treatment for 4 weeks then switched to tadalafil for 8 weeks. Dosing instructions were provided. Timing of dose and sexual intercourse was assessed through patient diaries for the final 4 weeks of each treatment period. A total of 2,760 men were enrolled: Asia 15.8%; ANZ 29.4%; CEE/ME 19.7%; LA 35.1%. The median time from dosing to intercourse was significantly increased during tadalafil treatment across all geographical regions; however, the magnitude of increase differed significantly by geography (P &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.0001). The Asian cohort demonstrated the shortest duration between dosing and sexual intercourse attempts (irrespective of drug), and altered sexual behavior the least upon switching to tadalafil. The ANZ cohort demonstrated the longest duration between dosing and sexual intercourse attempts (irrespective of drug), and altered sexual behavior the most upon switching to tadalafil. Men with a history of established sildenafil citrate use alter their dose-attempt behavior when treated with tadalafil irrespective of geography. However, the extent to which sexual behavior alters is not uniform across geographical regions, suggesting that dosing instructions and duration of drug effectiveness, in combination with personal and cultural preferences, may determine sexual behavior with PDE5 inhibitor use.
European Urology, Nov 1, 2006
Objectives: This study explored the efficacy of vardenafil in men with erectile dysfunction (ED) ... more Objectives: This study explored the efficacy of vardenafil in men with erectile dysfunction (ED) when taken 8 hours before sexual intercourse. Methods: A 10-week, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of vardenafil (5, 10 or 20 mg) was conducted in men with ED for >6 months who failed !50% of intercourse attempts during a 4-week treatment-free run-in period. Sexual Encounter Profile Question 3 (SEP3) was the primary efficacy measure; secondary measures included SEP2, International Index of Erectile Function-Erectile Function (IIEF-EF) domain score, Global Assessment Question (GAQ), Global Confidence Question (GCQ) and Erection Quality Scale (EQS). Adverse-event and safety monitoring were conducted throughout. Results: 383 patients were randomized to vardenafil (n = 194) or placebo (n = 189). Patients treated with vardenafil 8 hours before sexual activity achieved clinically meaningful (!18%) and statistically significantly greater least-squares mean per-patient SEP3 and SEP2 success rates over weeks 2-10, compared with patients receiving placebo (SEP3 69% vs 34%; SEP2 81% vs 51%; both p < 0.001). SEP3 and SEP2 measures demonstrated the significant superiority of vardenafil over placebo from week 2 onwards (p < 0.001). Measurements of IIEF-EF domain score, GAQ, GCQ and EQS showed that vardenafil led to significantly greater improvements in erectile function, compared with placebo (all p < 0.001). Vardenafil was generally well tolerated. Conclusions: The extended duration of efficacy of vardenafil up to 8 hours postdose may provide couples with more flexibility in their sexual life than anticipated.
The Journal of Sexual Medicine, Jul 1, 2008
Introduction. Homosexuality is a topic that needs to be integrated into the knowledge base of the... more Introduction. Homosexuality is a topic that needs to be integrated into the knowledge base of the practitioner of sexual medicine. Aim. To present to the reader a summary of the current literature on homosexuality and sexual orientation and address specifically issues that pertain to the relationship sexual orientation and sexual medicine practice. Main Outcome Measures. The information is presented in a continued medical education format, with a series of evaluation questions at the end of the activity. Methods. A review of the literature is presented and organized according to the authors' judgment of the value of the information as to provide the reader with an inclusive panorama of the issues covered. Results. Current concepts, debates, and need for further research are presented. Conclusions. The professional of sexual medicine needs to be aware of the various topics reviewed in this article as his or her involvement in the area of sexuality can create the expectation on the part of the patients of knowingness of all aspects of human sexuality. Sexual orientation is a complex area but considerable understanding has fortunately been achieved in many issues in reference to homosexuality and heterosexuality. Rubio-Aurioles E, and Wylie K. Sexual orientation matters in sexual medicine.
The Journal of Sexual Medicine, 2017
The focus of this article, the fourth in the series, Standards for Clinical Trials in Male and Fe... more The focus of this article, the fourth in the series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, is on aspects of clinical trial design and measurement that are specific to clinical trials for treatments of female sexual dysfunction. Challenges in this area include the limited extent of treatment development and clinical trial research across the spectrum of female sexual dysfunctions, changing regulatory considerations, changing diagnostic criteria for female sexual dysfunction, and the need to articulate assessment procedures to these changes. Discussion focuses on approaches to addressing these challenges in clinical trials in female sexual dysfunction.
European Urology Supplements, Mar 1, 2007
Introduction & Objectives: This was a prospective pooled analysis of two studies, one performed i... more Introduction & Objectives: This was a prospective pooled analysis of two studies, one performed in the USA and one in Europe/Mexico, performed to compare erectile function upon treatment with vardenafil versus sildenafil, in men with erectile dysfunction (ED). Material & Methods: The main inclusion criteria for the two randomised, double-blind crossover studies were: ED for >6 months, age ≥18 years, risk factors for cardiovascular disease (diabetes mellitus, hypertension and/or hyperlipidaemia) and a stable, heterosexual relationship for >6 months. After screening, patients were randomised to receive vardenafil 20 mg or sildenafil 100 mg for 4 weeks, followed by 1 week of washout, then 4 weeks' therapy with the second drug. The erectile function domain of the International Index of Erectile Function (IIEF-EF) was completed by patients at the end of each treatment period. The results were analysed for the overall population and for 18 subgroups, based on age, body mass index, smoking status, baseline IIEF-EF score, ED aetiology, ED duration, previous sildenafil use, or presence of diabetes mellitus status. Results: Across the two studies, 1,057 men were randomised to treatment. After 4 weeks' treatment, vardenafil provided greater improvement from baseline than sildenafil (nominal significance) in IIEF-EF score: least-squares (LS) mean change from baseline, 10.00 vs 9.40; p=0.0052. For all subgroups relating to smoking status, baseline IIEF-EF score, ED aetiology, ED duration, previous sildenafil use, or presence of diabetes mellitus status, numerically greater mean IIEF-EF improvement from baseline was observed with vardenafil versus sildenafil. The only subgroup where sildenafil provided numerically greater improvement was the age-group <45 years; for the other two age-groups (45-<65 years and ≥65 years), vardenafil provided greater improvements. In one subgroup, (body mass index <27) equal benefits were observed with both drugs, while vardenafil provided the greater improvement in men with body mass index ≥27. Conclusions: Vardenafil provided a greater overall improvement in IIEF-EF score than sildenafil (nominal significance). This finding was consistent across a broad range of ED patients.
Background: Erectile dysfunction is an entity that has a high prevalence worldwide. Aims: To comp... more Background: Erectile dysfunction is an entity that has a high prevalence worldwide. Aims: To compare the psychosocial clinical results of the analysis of a subgroup of Mexican men with erectile dysfunction that received tadalafil once a day (OaD), tadalafil on demand (PRN), or sildenafil PRN. Methods: The present study was a post hoc analysis of a subgroup of Mexican men taken from an open, randomized, cross-sectional study of men presenting with erectile dysfunction that were previously treated with phosphodiesterase type 5 (PDE5) inhibitors PRN. Results: Of the 378 patients included in the study, 84 were Mexican subjects. The change from the baseline to the endpoint was significantly greater in the Psychological and Interpersonal Relationship Scales (PAIRS) score of the Sexual Self-Confidence domain with tadalafil OaD vs. sildenafil PRN and also with tadalafil PRN vs. sildenafil PRN (differences of 0.25 ± 0.08 [0.10, 0.40]; p=0.001 and 0.28 ± 0.08; [0.13, 0.43]; p<0.001, respectively). No significant difference was observed with tadalafil OaD vs. tadalafil PRN (-0.03 ± 0.08 [-0.19, 0.12]; p=0.652). The changes in the PAIRS scores for the domains of Spontaneity and Time Concerns were significantly higher with tadalafil OaD vs. sildenafil PRN and with tadalafil PRN vs. sildenafil PRN. Three serious adverse events (SAEs) were reported. Conclusions: Mexican men with ED showed a superior improvement in sexual self-confidence, spontaneity, and reduced time concerns related to sexual activity when treated with tadalafil OaD and tadalafil PRN, as opposed to sildenafil PRN.
Blackwell Publishing Ltd eBooks, Jan 11, 2008
... Eusebio Rubio-Aurioles ... lifestyle Daily alcohol consumption 2.24 (0.895.64) Poor to fair ... more ... Eusebio Rubio-Aurioles ... lifestyle Daily alcohol consumption 2.24 (0.895.64) Poor to fair health 3.07 (1.386.81) Emotional problems or 3.20 (1.815.67) stress Sexual experience Thinks about sex less than 3.63 (1.578.40) once a week Any same sex activity ever 2.51 (1.10 ...
Revista Mexicana de Urología, May 1, 2014
Estudio aleatorizado, abierto con comparación cruzada de autocon anza se ual otros resultados cl ... more Estudio aleatorizado, abierto con comparación cruzada de autocon anza se ual otros resultados cl nicos terap uticos tras la administración de tadala l una ez al d a vs. tadala l o sildena l a demanda, en ombres me icanos con dis unción er ctil E. Rubio-Aurioles a,* , R. art nez-ontelon o b , F. Barrios c , S. Sorsaburu d ,. enne ese e. A. Re es-alle o
The Journal of Sexual Medicine, May 31, 2018
The Journal of Sexual Medicine, Oct 1, 2015
The Journal of Sexual Medicine, Feb 1, 2010
Introduction. The Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., text revision (... more Introduction. The Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., text revision (DSM-IV-TR) criteria for premature ejaculation (PE) have been criticized on multiple grounds including that the criteria lack precision, that the requirement of marked distress is inappropriate, and that the specification of etiological subtypes should be deleted. Since these criteria were originally adopted, there has been a tremendous gain in knowledge concerning PE. Aim. The goal of this manuscript is to review evidence relevant to diagnostic criteria for PE published since 1990. Method. Medline searches from 1990 forward were conducted using the terms PE, rapid ejaculation, ejaculatory disorder, and intravaginal ejaculatory latency. Early drafts of proposed alterations in diagnostic criteria were submitted to advisors. Main Outcome Measure. Expert opinion was based on review of evidence-based medical literature. Results. The literature search indicated possible alterations in diagnostic criteria for PE. Conclusions. It is recommended that the Diagnostic and Statistical Manual committee adopt criteria similar to those adopted by the International Society of Sexual Medicine. It is proposed that lifelong PE in heterosexual men be defined as ejaculation occurring within approximately 1 minute of vaginal penetration on 75% of occasions for at least 6 months. Field trials will be necessary to determine if these criteria can be applied to acquired PE and whether analogous criteria can be applied to ejaculatory latencies in other sexual activities. Serious consideration should be given to changing the name from PE to rapid ejaculation. The subtypes indicating etiology should be eliminated. Segraves RT. Considerations for an evidence-based definition of premature ejaculation in the DSM-V. J Sex Med 2010;7:672-689.
Uploads
Papers by Eusebio Rubio-Aurioles